Quick Links

Contact Us

Publications:

Late sodium current inhibition as a new cardioprotective approach.

Authors: Sharon L Hale|||John C Shryock|||Luiz Belardinelli|||Michael Sweeney|||Robert A Kloner

Journal: Journal of molecular and cellular cardiology

Publication Type: Journal Article

Date: 2008

DOI: 10.1016/j.yjmcc.2008.03.019

ID: 18462746

Affiliations:

Affiliations

    The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, USA; The Keck School of Medicine, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA 90017, USA.|||Cardiovascular Therapeutics, Inc, 1651 Page Mill Road, Palo Alto, CA 94304, USA. Electronic address: john.shryock@cvt.com.|||Cardiovascular Therapeutics, Inc, 1651 Page Mill Road, Palo Alto, CA 94304, USA.|||Depomed, Inc., 1360 O'Brien Drive, Menlo Park, CA 94025, USA.|||The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, USA; The Keck School of Medicine, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA 90017, USA.

Abstract

There is increasing evidence that the late sodium current of the sodium channel in myocytes plays a critical role in the pathophysiology of myocardial ischemia and thus is a potential therapeutic target in patients with ischemic heart disease. Ranolazine, an inhibitor of the late sodium current, reduces the frequency and severity of anginal attacks and ST-segment depression in humans, and unlike other antianginal drugs, ranolazine does not alter heart rate or blood pressure. In experimental animal models, ranolazine has been shown to reduce myocardial infarct size and to improve left ventricular function after acute ischemia and chronic heart failure. This article reviews published data describing the role of late sodium current and its inhibition by ranolazine in clinical and experimental studies of myocardial ischemia.

Chemical List

    Acetanilides|||Enzyme Inhibitors|||Piperazines|||Sodium Channel Blockers|||Sodium Channels|||Sodium|||Ranolazine